Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StateNew HampshireIn Committee
SB 256: establishing safety and care requirements for clinician-administered drugs.
Unknown Sponsor
SB 256 status: In Committee — Subcommittee Work Session: 10/07/2026 10:00 am GP 229 (updated Sep 17, 2026).
Source
LegiScan
Confidence
High
Analysis basis
LegiScan full bill text
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
66OUT OF 100
Score:66/100 civic fit
Risk:Moderate Risk
Impact:Moderate Impact 60/100
Constitutionality95%
Bipartisan70%
Public opinion80%
Bill summary
What changes
The bill regulates the delivery and management of 'clinician-administered drugs' (CADs) by prohibiting health insurers and PBMs from mandating white-bagging or brown-bagging without specific safety protocols and patient consent.
Who is affected
Patients requiring specialty infusion or injectable medications, healthcare providers, health insurance companies, and pharmacy benefit managers.
Requirements and enforcement
Providers and pharmacies must enter written agreements for drug handling; patients must provide written consent for brown-bagging arrangements; insurers cannot charge extra fees or limit coverage based on the source of the CAD.
Costs and funding
No direct state appropriations, but the Insurance Department notes a potential for increased insurance premiums as an indirect market cost.
When it takes effect
Effective January 1, 2027.
Potential benefits
Enhanced drug safety, increased patient autonomy, protection of provider choice, and clearer oversight of PBM distribution practices.
Risks and tradeoffs
Higher insurance premiums for the general public and potential for increased administrative burdens on the health insurance market.
What is still unknown
The precise magnitude of premium increases remains indeterminable.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Critical outlook
40%
Benefits
- Prevents discriminatory pricing and extra copays for patients
- Protects healthcare providers' established business models
- Increases choice for specialty drug procurement
Risks
- Potential for increased insurance premiums due to higher pharmacy costs
- Increased compliance and administrative costs for PBMs
- Loss of cost-saving mechanisms used by health maintenance organizations
Society
Positive outlook
75%
Benefits
- Empowers patients with autonomy in their healthcare treatment
- Standardizes safety procedures for delicate medications
- Reduces the patient burden of transporting complex drugs
Risks
- Potential for higher premiums reducing total healthcare affordability
- Possible service disruptions during transition to new protocols
- Increased stress for patients navigating new consent forms
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
Positive outlook
70%
Benefits
- Establishes clear legislative oversight of PBM practices
- Mandates written agreements for drug handling accountability
- Provides legal recourse for denied clinical drug access
Risks
- Ambiguity in interpreting medical necessity requirements
- Requires consistent regulatory enforcement by the Insurance Dept
- Potential for litigation regarding contract validity and compliance
Public Health & Safety
Positive outlook
80%
Benefits
- Ensures clinician oversight of drug integrity and storage
- Reduces patient-associated safety risks of transporting medication
- Improves compliance with complex medication dosing schedules
Risks
- Potential for supply chain delays in non-standard networks
- Variations in safety compliance across different clinic settings
- Risk of clinical errors during manual handling of specialty drugs
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
LegiScan
Official bill text or data from LegiScan.
Confidence
High
Information is complete and verified.
Analysis basis
LegiScan full bill text
Source used for this bill's analysis.
Source note
Implementation may result in increased insurance premiums for consumers as noted by the Insurance Department
Analysis scope
Economic impact is estimated as 'indeterminable' by the NH Insurance Dept
04
Where it stands
Official record- IntroducedComplete
- CommitteeCurrent
- Chamber votesUpcoming
- Final agreementUpcoming
- GovernorUpcoming
- EnactedUpcoming
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.